News

Only Moderate Immune Response for CoronaVac Vaccine in AAV

The CoronaVac COVID-19 vaccine has an excellent safety profile, but generates only a moderate immune response in people with ANCA-associated vasculitis (AAV), a clinical trial analysis found. Although the levels of vaccine-induced antibodies against SARS-CoV-2, the virus that causes COVID-19, declined over six months, a booster shot was shown…

AAV Patients at Higher Risk of Stroke, New Study Finds

People with ANCA-associated vasculitis (AAV) are at an increased risk of experiencing cardiovascular problems, such as a stroke, according to a new study done in South Korea. Indeed, AAV patients were found to have a more than two times higher risk of cardiovascular health problems than individuals without any…

Hemoglobin Levels Predict Course of AAV-Related Kidney Disease

Intensive care stays are more likely if oxygen-carrying hemoglobin levels are low at hospital admission in adults with kidney disease caused by ANCA-associated vasculitis (AAV), an analysis of medical records found. Severe kidney injury was the primary reason for intensive care unit (ICU) admission in these patients and associated…

Higher Healthcare Costs in Year Before Diagnosis, Analysis Finds

In the year before being diagnosed with ANCA-associated vasculitis (AAV), Medicare beneficiaries had significantly higher use and costs of healthcare than those without AAV, an analysis found. According to researchers, earlier identification of AAV is necessary to provide patients with appropriate care and potentially reduce costs and healthcare use.

S. aureus Infections in the Nose Not Tied to Ear, Nose, and Throat Disease

Nasal Staphylococcus aureus infections don’t appear to influence disease activity in ANCA-associated vasculitis (AAV) patients with ear, nose, and throat involvement, a study suggests. Treatment with antibiotics to clear S. aureus infections didn’t reduce disease activity either. “Our study shows no difference in systemic and local disease activity between…

Cemiplimab Partially Treats Skin Cancer in Man With AAV

An 87-year-old man with ANCA-associated vasculitis (AAV), kidney disease and cutaneous squamous cell carcinoma (cSSC) — a type of skin cancer — partially responded to cemiplimab treatment without developing kidney complications or immune-related side effects. However, his response to cemiplimab was delayed as the tumor initially grew,  but regressed…